Viva Vision Biotech Overview
- Year Founded
-
2016
- Status
-
IPO Registration
- Employees
-
63
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
26
Viva Vision Biotech General Information
Description
Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. The company provides clinical-stage drug candidates and a robust R&D pipeline, enabling patients and healthcare systems with novel treatment options, improved efficacy, and solutions for unmet ocular medical needs.
Contact Information
Website
www.vivavisionbio.comCorporate Office
- Room 4020, Building B, North Zone, Gene Valley
- Ouhai District
- Wenzhou, Zhejiang 900000
- China
Corporate Office
- Room 4020, Building B, North Zone, Gene Valley
- Ouhai District
- Wenzhou, Zhejiang 900000
- China
Viva Vision Biotech Timeline
Viva Vision Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. IPO | 13-Feb-2026 | Announced | Generating Revenue | |||
| 13. Secondary Transaction - Private | 01-Jan-2026 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series D2) | 27-Nov-2025 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Private | 01-May-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series D2) | 31-Dec-2024 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 01-Apr-2023 | Completed | Clinical Trials - Phase 2 | |||
| 8. Secondary Transaction - Private | 01-Nov-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Secondary Transaction - Private | 01-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series D) | 09-Aug-2021 | $46.3M | $65.6M | Completed | Clinical Trials - Phase 2 | |
| 5. Secondary Transaction - Private | 01-Jan-2021 | $19.3M | Completed | Clinical Trials - Phase 2 |
Viva Vision Biotech Comparisons
Industry
Financing
Details
Viva Vision Biotech Competitors (26)
One of Viva Vision Biotech’s 26 competitors is Novaliq, a Venture Capital-Backed company based in Heidelberg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novaliq | Venture Capital-Backed | Heidelberg, Germany | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| EyeD Pharma | Venture Capital-Backed | Seraing, Belgium | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Viva Vision Biotech Patents
Viva Vision Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026201113-A1 | Intranasal compositions comprising a jak inhibitor for inflammatory upper respiratory disease | Pending | 28-Mar-2025 | ||
| WO-2026170436-A1 | Derivative of jak inhibitor | Pending | 14-Feb-2025 | ||
| WO-2026119018-A1 | Ngf-containing ophthalmic composition and use thereof | Pending | 02-Dec-2024 | ||
| WO-2026082117-A1 | Jak inhibitors for treating inflammatory eye conditions | Pending | 17-Oct-2024 | ||
| WO-2025160705-A1 | Preparation method for lfa-1 inhibitor | Pending | 29-Jan-2024 |
Viva Vision Biotech Signals
Viva Vision Biotech Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wanlian Tianze Capital Investment | Venture Capital | Minority | ||
| Guangdong Technology Financial Group | Government | Minority | ||
| Guangzhou Industrial Investment Holding Group | Government | Minority | ||
| Hunan Energy Group | Corporation | Minority | ||
| The Innovation and Technology Commission | Government | Minority |
Viva Vision Biotech Investments (3)
Viva Vision Biotech’s most recent deal was a Joint Venture with Joint Venture (VivaVision / Jiangxi Shanliang Pharmaceutical). The deal was made on 06-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (VivaVision / Jiangxi Shanliang Pharmaceutical) | 06-Jun-2024 | Joint Venture | Other Consumer Durables | ||
| Therapies for Retinal Diseases (Everads / VivaVision Biopharma) | 06-Jan-2023 | Joint Venture | Drug Discovery | ||
| E-nitiateBio | 23-Nov-2020 | Joint Venture | Drug Discovery |
Viva Vision Biotech FAQs
-
When was Viva Vision Biotech founded?
Viva Vision Biotech was founded in 2016.
-
Where is Viva Vision Biotech headquartered?
Viva Vision Biotech is headquartered in Wenzhou, China.
-
What is the size of Viva Vision Biotech?
Viva Vision Biotech has 63 total employees.
-
What industry is Viva Vision Biotech in?
Viva Vision Biotech’s primary industry is Drug Discovery.
-
Is Viva Vision Biotech a private or public company?
Viva Vision Biotech is a Private company.
-
What is Viva Vision Biotech’s current revenue?
The current revenue for Viva Vision Biotech is .
-
How much funding has Viva Vision Biotech raised over time?
Viva Vision Biotech has raised $107M.
-
Who are Viva Vision Biotech’s investors?
Wanlian Tianze Capital Investment, Guangdong Technology Financial Group, Guangzhou Industrial Investment Holding Group, Hunan Energy Group, and The Innovation and Technology Commission are 5 of 26 investors who have invested in Viva Vision Biotech.
-
Who are Viva Vision Biotech’s competitors?
Novaliq, EyePoint, EyeD Pharma, Astellas Pharma, and Crinetics Pharmaceuticals are some of the 26 competitors of Viva Vision Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process